Overview Financials News + Filings Key Docs Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Mar-31-21 | Dec-31-20 | Mar-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | S-1/A | 10-K | S-1 | 10-K | S-1 | 10-K | 10-K | S-1/A |
| Revenues: |
| BioNexus Malaysia | 0.1 | 1.5 | | 0.1 | | | | |
| Chemrex | 10,832.9 | 11.8 | | 11.3 | | | | |
| Total revenues | 10.9 | 13.4 | 13.4 | 11.4 | 11.4 | 0.1 | 0.2 | 0.1 |
| Revenue growth [+] | -18.2% | 17.3% | 17.3% | 8872.0% | | -40.2% | 97.2% | |
| BioNexus Malaysia | -93.7% | 1030.3% | | | | | | |
| Chemrex | 91340.8% | 5.2% | | | | | | |
| Cost of goods sold | 11.2 | 11.2 | 11.2 | 9.7 | 9.7 | 0.1 | 0.2 | 0.0 |
| Gross profit | -0.3 | 2.2 | 2.2 | 1.7 | 1.7 | 0.1 | 0.0 | 0.1 |
| Gross margin | -2.7% | 16.4% | 16.4% | 15.1% | 15.1% | 44.0% | 13.5% | 73.2% |
| Selling, general and administrative [+] | -11.2 | 1.2 | 1.2 | 1.3 | 1.3 | 0.4 | 0.2 | 0.2 |
| General and administrative | | 1.2 | 1.2 | 1.3 | 1.3 | 0.4 | 0.2 | |
| Other operating expenses | 11.2 | -0.1 | -2.4 | -0.9 | -2.7 | 0.0 | -0.3 | 0.0 |
| EBITDA [+] | -0.2 | 1.1 | | 1.4 | | -0.2 | 0.1 | |
| EBITDA growth | -117.4% | -15.9% | 11.3% | -683.2% | | -332.8% | -184.2% | |
| EBITDA margin | -1.8% | 8.6% | 25.4% | 12.0% | 26.8% | -184.3% | 47.3% | -110.9% |
| Depreciation and amortization | 0.1 | 0.1 | | 0.1 | | 0.0 | 0.0 | |
| EBIT [+] | -0.3 | 1.1 | 3.4 | 1.3 | 3.1 | -0.3 | 0.1 | -0.1 |
| EBIT growth | -127.6% | -17.1% | 11.3% | -562.0% | | -560.3% | -150.2% | |
| EBIT margin | -2.7% | 7.9% | 25.4% | 11.2% | 26.8% | -217.2% | 28.2% | -110.9% |
| Interest expense | 0.0 | | | | | | | |
| Interest expense | 0.0 | | | | | | | |
| Other income (expense), net [+] | | 0.0 | -2.4 | 0.0 | -1.8 | | -0.1 | 0.0 |
| Gain (loss) on foreign currency transactions | | -0.2 | | 0.2 | | 0.0 | | |
| Other | -0.2 | 0.1 | | 0.9 | | 0.0 | 0.3 | |
| Pre-tax income | -0.3 | 1.0 | 1.0 | 1.3 | 1.3 | -0.3 | 0.0 | -0.1 |
| Income taxes | 0.1 | 0.0 | -0.3 | 0.0 | -0.2 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.1% | | | 478.3% | 3.4% |
| Net income | -0.4 | 0.8 | 0.0 | 1.1 | 0.0 | -0.2 | 0.0 | -0.1 |
| Net margin | -3.3% | 5.6% | 0.0% | 9.6% | 0.0% | -194.1% | 12.5% | -114.9% |
| |
| Basic EPS [+] | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Growth | -146.9% | -58.7% | | -472.5% | | -815.6% | -117.2% | |
| Diluted EPS [+] | $0.00 | $0.00 | $0.00 | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Growth | -146.9% | -58.7% | | -472.5% | | -815.6% | -117.2% | |
| |
| Shares outstanding (basic) [+] | 172.9 | 171.2 | 171.2 | 102.9 | 102.9 | 86.4 | 66.3 | 53.3 |
| Growth | 1.0% | 66.4% | 66.4% | 19.2% | | 30.2% | 24.5% | |
| Shares outstanding (diluted) [+] | 172.9 | 171.2 | 171.2 | 102.9 | 102.9 | 86.4 | 66.3 | 53.3 |
| Growth | 1.0% | 66.4% | 66.4% | 19.2% | | 30.2% | 24.5% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|